RTP Mobile Logo
Select Publications

Chu AJ. Tissue factor, blood coagulation, and beyond: An overview. Int J Inflam 2011;2011:367284. Abstract

Cocco E et al. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer 2011;11:263. Abstract

Forster Y et al. Tissue factor and tumor: Clinical and laboratory aspects. Clin Chim Acta 2006;364(1-2):12-21. Abstract

Konstantopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5(8):1141-9. Abstract

Makker V et al. Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC). ESMO 2019;Abstract 994O.

Matulonis UA et al. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. ASCO 2020;Abstract 6005.

Pujade-Lauraine E et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. SGO 2019;Abstract LBA1.

Ruf W et al. Tissue factor and cell signaling in cancer progression and thrombosis. J Thromb Haemost 2011;9(Suppl 1):306-15. Abstract

Swisher E et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18(1):75-87. Abstract

van den Berg YW et al. The relationship between tissue factor and cancer progression: Insights from bench and bedside. Blood 2012;119(4):924-32. Abstract

Versteeg HH. Tissue factor: Old and new links with cancer biology. Semin Thromb Hemost 2015;41(7):747-55. Abstract

Zamarin D et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRG Oncology study. J Clin Oncol 2020;38(16):1814-23. Abstract